微針流感疫苗市場- 按產品類型（實心、空心、塗層、溶解微針）、疫苗類型（三價、四價）、流感類型（甲型流感[H1N1、H3N1]、乙型流感）、全球預測（2024 - 2032）

Microneedle Flu Vaccine Market - By Product Type (Solid, Hollow, Coated, Dissolving Microneedle), Vaccine Type (Trivalent, Quadrivalent), Flu Type (Influenza A [H1N1, H3N1], Influenza B), Global Forecast (2024 - 2032)

出版日期: 2024年06月03日 | 出版商:

Global Market Insights Inc. | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在開發更有效、更有效率的微針設計的研究活動不斷增加的推動下，微針流感疫苗市場規模從 2024 年到 2032 年的複合年成長率將達到 6.1%。例如，2023年1月，CD Formulation推出了可溶性微針製備服務，以提高藥物輸送效率。可生物分解聚合物和金屬等材料的進步正在增強流感疫苗的輸送，同時減少浪費。微針塗層的創新也提高了疫苗的穩定性和功效，增加了產品需求。

微針流感疫苗市場分為產品類型、疫苗類型、流感類型和地區。

從產品類型來看，2024年至2032年，塗層微針細分市場的產業價值可能會出現強勁成長。，從而更容易為大量人群快速接種疫苗。微針技術、材料科學和疫苗配方領域的不斷進步也推動了更有效和方便用戶使用的塗層微針疫苗的開發。

根據流感類型，B 型流感細分市場的微針流感疫苗市場預計將在 2024 年至 2032 年期間以強勁的複合年成長率擴張。這些疫苗的設計目的是比傳統的肌肉注射疼痛更輕、更容易注射，並且可能更有效。憑藉積極的監管框架，微針疫苗已成為流感疫苗接種的標準解決方案，可改善公共衛生結果並減輕季節性流感流行的負擔。正在進行的研發也可能產生更有效和方便用戶使用的疫苗接種選擇。

從地區來看，由於政府的大力支持，預計亞太地區微針流感疫苗產業從 2024 年到 2032 年將實現利潤豐厚的複合年成長率。該地區對無痛、方便且經濟有效的疫苗接種方法的關注使微針疫苗成為改善公共衛生結果的有前途的解決方案。亞太地區人口眾多且多樣化，獲得醫療保健的機會也各不相同，這也將有利於人們對產品的偏好。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

3M
Becton, Dickinson and Company
Corium International, Inc.
CosMED Pharmaceuticals Co., Ltd
FluGen, Inc
Sanofi

簡介目錄

Product Code: 9724

Microneedle Flu Vaccine Market size will witness 6.1% CAGR from 2024-2032, driven by rising research activities for the development of more effective and efficient microneedle designs. For example, in January 2023, CD Formulation introduced its dissolving microneedle preparation services for enhancing drug delivery efficiency. Advancements in materials, such as biodegradable polymers and metals, are enhancing the delivery of the flu vaccines while reducing waste. Innovations in coatings used on microneedles are also improving the stability and efficacy of vaccines, adding to the product demand.

The microneedle flu vaccine market is segmented into product type, vaccine type, flu type, and region.

In terms of product type, the industry value from the coated microneedle segment may witness strong growth from 2024 to 2032. As coated microneedle patches can be self-administered, they reduce the need for healthcare professionals, making it easier to vaccinate the large population quickly. The ongoing advances in microneedle technology, materials science, and vaccine formulation area also driving the development of more effective and user-friendly coated microneedle vaccines.

Based on flue type, the microneedle flu vaccine market from the influenza B segment is expected to expand at robust CAGR from 2024-2032. These vaccines are designed to be less painful, easier to administer, and potentially more effective than traditional intramuscular injections. With positive regulatory frameworks, microneedle vaccines have turned standard solutions for influenza vaccination for improving public health outcomes and reducing the burden of seasonal flu epidemics. The ongoing R&D is also likely to yield more effective and user-friendly vaccination options.

Regionally, the Asia Pacific microneedle flu vaccine industry is projected to witness lucrative CAGR from 2024 to 2032 due to the surging government support. The focus on painless, convenient, and cost-effective vaccination methods in the region is making microneedle vaccines a promising solution for improving public health outcomes. The presence of a large and diverse population with varying levels of access to healthcare will also favor the product preference in APAC.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of influenza and viral infections
  - 3.2.1.2 Ease of administration
  - 3.2.1.3 Growing investment in research and development of microneedle technology
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Complications and risks associated with microneedles
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Solid microneedle
5.3 Hollow microneedle
5.4 Coated microneedle
5.5 Dissolving microneedle

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Trivalent flu vaccine
6.3 Quadrivalent flu vaccine

Chapter 7 Market Estimates and Forecast, By Flu Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Influenza A
- 7.2.1 H1N1
- 7.2.2 H3N1
7.3 Influenza B

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa